astria therapeutics glp-1 receptor agonist weight management diabetes treatments cardinal health GLP-1 Agonists: Revolutionizing the Treatment of Obesity, but Are They Enough? - Eric Velazquez, MD - Bariatric Surgeon GLP-1 Receptor Agonist Market Size

The SCALE clinical trials were designed to assess the effectiveness and safety of this agent for weight loss in patients with obesity or overweight (BMI 27kg/m2) with comorbidities

Letarouilly, J

For example, 88 percent of cardiologists surveyed said that they had prescribed GLP-1RAs to treat cardiovascular disease

10.1016/j.pmn.2022.05.005 [DOI] [PubMed] [Google Scholar] 79.Pandey S, Mangmool S, Madreiter-Sokolowski CT, Wichaiyo S, Luangmonkong T, Parichatikanond W (2023) Exendin-4 protects against high glucose-induced mitochondrial dysfunction and oxidative stress in SH-SY5Y neuroblastoma cells through GLP-1 receptor/Epac/Akt signaling

NF-B inhibition by GLP-1

FDA-approved for chronic weight management